amyloidosis

IFB-088 acetate, a benzyl guanidine derivative, is used to treat diseases and cancers associated with the PPP1R15A pathway and associated with protein misfolding stress, Examples include tau disease, synaptic riboprotein disease, polyglutamine and polyalanine diseases, leukodystrophy, cystic fibrosis, multiple sclerosis, lysosome storage disorders, amyloidosis diseases, inflammation, metabolic disorders, cardiovascular diseases, osteoporosis, neurological trauma, and more.

AG-10 (Acoramidis) is an orally active and selective kinetic stabilizer of TTR (transthyretin). AG-10 exhibits activity for WT and V122I-TTR. AG-10 is used in the study of transthyretin amyloidosis.

Tauroursodeoxycholate (UR 906), also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Acoramidis hydrochloride (Alxn2060 hydrochloride) is an orally active and selective kinetic stabilizer of WT and V122I- TTR (transthyretin) . Acoramidis hydrochloride is used in the study for transthyretin amyloidosis.

Eprodisate disodium (NC-503) is a negatively charged sulfonated inhibitor of fibrillogenesis, that can be used in the treatment of amyloid A (AA) amyloidosis.

Inotersen sodium, also known as ISIS-420915 sodium, is a 2′-O-methoxyethyl-modified antisense oligonucleotide compound. It effectively inhibits transthyretin (TTR) protein production by targeting the TTR RNA transcript, thereby reducing TTR transcript levels. Inotersen sodium holds potential for research on hereditary TTR amyloidosis polyneuropathy.

Patisiran sodium is a double-stranded small interfering RNA (siRNA) that selectively targets a specific sequence within the transthyretin (TTR) messenger RNA (mRNA). By doing so, it effectively blocks the hepatic synthesis of both mutant and wild-type TTR. Patisiran sodium has significant applications in the field of hereditary TTR amyloidosis research.

Revusiran (ALN-TTRSC) is a first-generation short interfering RNA (siRNA) that specifically targets transthyretin (TTR) mRNA. It is utilized in TTR-mediated amyloidosis research.

Vutrisiran (ALN-TTRsc02) is an investigational, liver-directed small interfering ribonucleic acid (siRNA) compound designed for research on transthyretin (TTR)-mediated amyloidosis.

WAY-612453 is an active compound utilized in researching amyloid diseases and synucleinopathies.

Anti-amyloid agent-1 is a potent compound that inhibits amyloid aggregation, offering a promising approach for research into the treatment of amyloidosis [1].

PITB, a selective and orally active transthyretin (TTR) aggregation inhibitor, is utilized in transthyretin amyloidosis (ATTR) disease research [1].

Birtamimab (NEOD001) is a monoclonal antibody under investigation for its ability to selectively target and eliminate amyloid in the treatment of light chain amyloidosis [1].

Tauroursodeoxycholic Acid-d4 Sodium Salt is a deuterated compound of Tauroursodeoxycholic Acid Sodium Salt. Tauroursodeoxycholic Acid Sodium Salt has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Tauroursodeoxycholic-2,2,3,4,4-d5 Acid is a deuterated compound of Tauroursodeoxycholic Acid. Tauroursodeoxycholic Acid has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

PD146176 (NSC-168807) is an inhibitor of 15-Lipoxygenase (15-LO) , it inhibits rabbit reticulocyte 15-LO with Ki of 197 nM and IC50 of 0.54 μM. PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice.

Tauroursodeoxycholic-d4 Acid is a deuterated compound of Tauroursodeoxycholic Acid. Tauroursodeoxycholic Acid has a CAS number of 14605-22-2. Tauroursodeoxycholate, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. Tauroursodeoxycholate is the more hydrophilic form of ursodeoxycholic acid, which is the more abundant naturally produced bile acid in humans.Tauroursodeoxycholate is being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.

Eplontersen, a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide, targets transthyretin (TTR) mRNA to suppress the synthesis of both variant and wild-type TTR proteins. The accumulation of misfolded TTR proteins contributes to the formation of amyloid fibrils in the heart and peripheral nerves, resulting in amyloid TTR (ATTR) amyloidosis [1] [2] [3].

amyloid P-IN-1 can be used in studies about diseases with depletion of serum amyloid P components such as Alzheimer's disease, amyloidosis, osteoarthritis, and type 2 diabetes mellitus.

Eprodisate is a novel compound specifically developed to disrupt the interactions between amyloidogenic proteins and glycosaminoglycans, effectively impeding the polymerization of amyloid fibrils and their deposition in tissues. This compound shows potential for delaying the advancement of AA amyloidosis-related renal disease and could apply to various forms of amyloidosis.

Tauroursodeoxycholate sodium (TUDC) is an endoplasmic reticulum (ER) stress inhibitor, used for the treatment of gallstones and liver cirrhosis.

Tauroursodeoxycholate dihydrate is an endoplasmic reticulum stress inhibitor. Tauroursodeoxycholate also inhibits ERK. Tauroursodeoxycholate significantly decreases the expression of apoptosis molecules, such as caspase-3 and caspase-12.